Memantine Hydrochloride Oral
Generic Name: memantine hydrochloride oral
Brand Names:
Memantine Hydrochloride
11 DESCRIPTION Memantine hydrochloride is an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula: The molecular formula is C 12 H 21 N•HCl and the molecular weight is 215.76. Memantine HCl occurs as a fine white to off-white powder and is soluble in water.
Overview
11 DESCRIPTION Memantine hydrochloride is an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula: The molecular formula is C 12 H 21 N•HCl and the molecular weight is 215.76. Memantine HCl occurs as a fine white to off-white powder and is soluble in water.
Uses
1. INDICATIONS AND USAGE Memantine hydrochloride is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. (1)
Dosage
2. DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride is 5 mg (2.5 mL) once daily. The dose should be increased in 5 mg increments to 10 mg/day (2.5 mL twice daily), 15 mg/day (2.5 mL and 5 mL as separate doses), and 20 mg/day (5 mL twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day (5 mL twice daily). Dosing Titration Schedule Memantine hydrochloride can be taken with or without food. If a patient misses a single dose of memantine hydrochloride, that patient should not double up on the next dose. The next dose should be taken as scheduled.
Side Effects
6. ADVERSE REACTIONS Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Memantine hydrochloride was evaluated in eight double-blind placebo-controlled trials involving a total of 1862 dementia (Alzheimers disease, vascular dementia) patients (940 patients treated with memantine hydrochloride and 922 patients treated with placebo) for a treatment period up to 28 weeks.
Interactions
7 DRUG INTERACTIONS 7.1 Drugs that Make the Urine Alkaline The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.
Warnings
5. WARNINGS AND PRECAUTIONS Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine. (5.1, 7.1) 5.1 Genitourinary Conditions Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine [see Drug Interactions (7.1)]. 4. CONTRAINDICATIONS Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. (4)
Pregnancy
8.1 Pregnancy Pregnancy Category B There are no adequate and well-controlled studies of memantine in pregnant women. Memantine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [MRHD] on a mg/m 2 basis).
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING Memantine Hydrochloride Oral Solution 2 mg/mL (10 mg = 5 mL) 12 fl. oz. (360 mL) bottle NDC #13925-540-12 Store at 25°C (77°F); excursions permitted between 15° to 30°C (59°to 86°F). [see USP Controlled Room Temperature.] Dispense in tightly closed containers.
Frequently Asked Questions
What is Memantine Hydrochloride Oral used for?▼
1. INDICATIONS AND USAGE Memantine hydrochloride is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. (1)
What are the side effects of Memantine Hydrochloride Oral?▼
6. ADVERSE REACTIONS Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Memantine hydrochloride was evaluated in eight double-blind placebo-controlled trials involving a total of 1862 dementia (Alzheimers disease, vascular dementia) patients (940 patients treated with memantine hydrochloride and 922 patients treated with placebo) for a treatment period up to 28 weeks.
Can I take Memantine Hydrochloride Oral during pregnancy?▼
8.1 Pregnancy Pregnancy Category B There are no adequate and well-controlled studies of memantine in pregnant women. Memantine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [MRHD] on a mg/m 2 basis).
What are the important warnings for Memantine Hydrochloride Oral?▼
5. WARNINGS AND PRECAUTIONS Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine. (5.1, 7.1) 5.1 Genitourinary Conditions Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine [see Drug Interactions (7.1)]. 4. CONTRAINDICATIONS Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. (4)
Related Medications
Adrenalinum, Adrenocorticotrophin (30x), Agrimonia Eupatoria, Flos, Anacardium Orientale, Antimonium Crudum, Calcarea Carbonica, Castanea Sativa, Flos, Cortisone Aceticum, Fucus Vesiculosus, Hypothalamus, Kali Bichromicum, Oleander, Pituitarum Posterium, Sabadilla, Staphysagria, And Thyroidinum.
adrenalinum, adrenocorticotrophin (30x), agrimonia eupatoria, flos, anacardium orientale, antimonium crudum, calcarea carbonica, castanea sativa, flos, cortisone aceticum, fucus vesiculosus, hypothalamus, kali bichromicum, oleander, pituitarum posterium, sabadilla, staphysagria, and thyroidinum.
Adrenocorticotropic Hormone [EPC]
Equal volumes of each HPUS ingredient in 10X, 30X, and 1LM potencies, unless otherwise noted. Active ingredients Purpose † **“HPUS” indicates the active ingredients are in the official Homeopathic Pharmacopeia of the United States. Adrenalinum..............................................increased appetite, indigestion Adrenocorticotrophin (30X) ................................................fat face, neck Agrimonia eupatoria, flos............................................................crav
Histaminum Hydrochloricum,thyroidinum, Aconitum Nap., Arsenicum Alb., Bryonia, Cactus, Calc. Fluor., Ceanothus, Cinchona, Convallaria, Digitalis, Gelsemium, Glonoinum, Hydrocoyle, Kali Carb., Lachesis, Naja, Nat Carb., Nat Mur., Nux Vom., Phosphorus, Pullsatilla, Rhus Toxicodendron, Strophanthus Hispidus, Sulphur, Echinacea
histaminum hydrochloricum,thyroidinum, aconitum nap., arsenicum alb., bryonia, cactus, calc. fluor., ceanothus, cinchona, convallaria, digitalis, gelsemium, glonoinum, hydrocoyle, kali carb., lachesis, naja, nat carb., nat mur., nux vom., phosphorus, pullsatilla, rhus toxicodendron, strophanthus hispidus, sulphur, echinacea
Nitrate Vasodilator [EPC]
OTC - PURPOSE SECTION Formulated for associated symptoms such as dizziness, fatigue, weakness, tingling and numb or cold extremities.
Polygonatum Cepa
polygonatum cepa
Copper-containing Intrauterine Device [EPC]
Uses: Promotes skin regeneration and minimizes scars.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.